688382 益方生物-U
未开盘 10-08 09:30:00
资讯
新帖
简况
益方生物科技（688382）9月28日主力资金净买入246.74万元
证券之星 · 09-29
益方生物科技（688382）9月28日主力资金净买入246.74万元
翰森制药TYK2新药III期告捷，直面进口、国产、生物制剂三面挤压：商业化突围挑战重重，第二增长曲线仍待验证
同花顺 · 09-23
翰森制药TYK2新药III期告捷，直面进口、国产、生物制剂三面挤压：商业化突围挑战重重，第二增长曲线仍待验证
每周股票复盘：益方生物（688382）重新递表港交所拟发行H股
证券之星 · 08-30
每周股票复盘：益方生物（688382）重新递表港交所拟发行H股
益方生物（688382）披露召开2026年半年度业绩说明会公告，8月25日股价上涨0.52%
证券之星 · 08-25
益方生物（688382）披露召开2026年半年度业绩说明会公告，8月25日股价上涨0.52%
益方生物：重新递交H股发行上市申请
证券之星 · 08-23
益方生物：重新递交H股发行上市申请
每周股票复盘：益方生物（688382）股东户数减少16.7%
证券之星 · 08-23
每周股票复盘：益方生物（688382）股东户数减少16.7%
默沙东研发中国签署合作协议，携手益方生物推进小分子肿瘤药物临床开发
美股速递 · 08-11
默沙东研发中国签署合作协议，携手益方生物推进小分子肿瘤药物临床开发
默沙东与益方生物签署合作协议 推进肿瘤领域小分子药物临床开发
智通财经 · 08-11
默沙东与益方生物签署合作协议 推进肿瘤领域小分子药物临床开发
股市必读：益方生物（688382）8月4日董秘有最新回复
证券之星 · 08-05
股市必读：益方生物（688382）8月4日董秘有最新回复
每周股票复盘：益方生物（688382）因股价涨幅达15%登龙虎榜
证券之星 · 07-26
每周股票复盘：益方生物（688382）因股价涨幅达15%登龙虎榜
益方生物（688382）披露签订募集资金专户存储四方监管协议公告，7月22日股价下跌1.65%
证券之星 · 07-22
益方生物（688382）披露签订募集资金专户存储四方监管协议公告，7月22日股价下跌1.65%
股市必读：益方生物（688382）登7月3日交易所龙虎榜
证券之星 · 07-06
股市必读：益方生物（688382）登7月3日交易所龙虎榜
7月3日益方生物（688382）龙虎榜数据：机构净买入1.22亿元，北向资金净卖出7665.08万元
证券之星 · 07-03
7月3日益方生物（688382）龙虎榜数据：机构净买入1.22亿元，北向资金净卖出7665.08万元
益方生物（688382）披露关于变更公司注册资本并修订《公司章程》的公告，7月2日股价上涨4.79%
证券之星 · 07-02
益方生物（688382）披露关于变更公司注册资本并修订《公司章程》的公告，7月2日股价上涨4.79%
新股消息 | 益方生物(688382.SH)港股IPO招股书失效
智通财经 · 07-02
新股消息 | 益方生物(688382.SH)港股IPO招股书失效
每周股票复盘：益方生物（688382）授出657.0981万股限售股
证券之星 · 06-28
每周股票复盘：益方生物（688382）授出657.0981万股限售股
益方生物（688382）发布向2026年限制性股票激励计划激励对象授予限制性股票的公告，6月24日股价上涨3.02%
证券之星 · 06-24
益方生物（688382）发布向2026年限制性股票激励计划激励对象授予限制性股票的公告，6月24日股价上涨3.02%
每周股票复盘：益方生物（688382）2026年限制性股票激励计划获通过
证券之星 · 06-20
每周股票复盘：益方生物（688382）2026年限制性股票激励计划获通过
益方生物（688382）披露2025年年度股东会决议公告，6月18日股价上涨2.81%
证券之星 · 06-18
益方生物（688382）披露2025年年度股东会决议公告，6月18日股价上涨2.81%
每周股票复盘：益方生物（688382）新增1,243,513股上市
证券之星 · 06-07
每周股票复盘：益方生物（688382）新增1,243,513股上市
加载更多
公司概况
公司名称：
益方生物科技(上海)股份有限公司
所属行业：
医药制造业
上市日期：
2022-07-25
主营业务：
益方生物科技(上海)股份有限公司的主营业务是创新药物的研发、生产和销售。公司的主要产品是贝福替尼、格索雷塞。
发行价格：
18.12
{"stockData":{"symbol":"688382","market":"SH","secType":"STK","nameCN":"益方生物-U","latestPrice":19.07,"timestamp":1791421298000,"preClose":19.07,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":580000000,"shares":580000000,"eps":-0.5772,"marketStatus":"未开盘","change":0,"latestTime":"10-08 09:30:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.5772,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791423000000},"marketStatusCode":0,"adr":0,"adjPreClose":19.07,"symbolType":"stock_kcb","openAndCloseTimeList":[[1791423000000,1791430200000],[1791435600000,1791442800000]],"highLimit":20.98,"lowLimit":17.16,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":579592004,"isCdr":false,"pbRate":7.83,"roa":"--","roe":"--","epsLYR":-0.5479,"committee":0,"marketValue":11053000000,"turnoverRate":0,"status":2,"floatMarketCap":11053000000},"requestUrl":"/m/hq/s/688382","defaultTab":"news","newsList":[{"id":"2671269689","title":"益方生物科技（688382）9月28日主力资金净买入246.74万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671269689","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671269689?lang=zh_cn&edition=full","pubTime":"2026-09-29 08:38","pubTimestamp":1790642312,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月28日收盘，益方生物科技报收于17.65元，下跌5.87%，换手率2.79%，成交量16.16万手，成交额2.88亿元。近5日资金流向一览见下表：益方生物科技融资融券信息显示，融资方面，当日融资买入1851.88万元，融资偿还807.14万元，融资净买入1044.74万元，连续3日净买入累计1897.76万元。益方生物科技主营业务：致力于研制出具有自主知识产权、中国创造并面向全球的创新药物,持之以恒地为患者提供更加安全、有效、可负担的治疗方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900007455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","HBImain","688382","159837"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669173759","title":"翰森制药TYK2新药III期告捷，直面进口、国产、生物制剂三面挤压：商业化突围挑战重重，第二增长曲线仍待验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2669173759","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669173759?lang=zh_cn&edition=full","pubTime":"2026-09-23 08:13","pubTimestamp":1790122380,"startTime":"0","endTime":"0","summary":"翰森制药（03692.HK）旗下口服TYK2抑制剂在III期临床中达到主要终点，标志着其在自身免疫疾病领域迎来重要里程碑。9月21日，翰森制药公告称，自研酪氨酸激酶2（TYK2）选择性变构抑制剂HS-10 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260923/c680191975.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260923/c680191975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688336","688382","688428","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663045972","title":"每周股票复盘：益方生物（688382）重新递表港交所拟发行H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2663045972","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663045972?lang=zh_cn&edition=full","pubTime":"2026-08-30 10:04","pubTimestamp":1788055453,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，益方生物报收于20.09元，较上周的20.0元上涨0.45%。本周关注点公司公告汇总：益方生物重新向港交所递交H股上市申请。公司公告汇总益方生物关于重新向香港联合交易所有限公司递交H股发行上市申请并刊发申请资料的公告益方生物科技（上海）股份有限公司于2026年8月21日重新向香港联合交易所有限公司递交发行H股股票并在香港联交所主板上市的申请，并于同日在香港联交所网站刊发了申请资料。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000004773.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239","HEXmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662758915","title":"益方生物（688382）披露召开2026年半年度业绩说明会公告，8月25日股价上涨0.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662758915","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662758915?lang=zh_cn&edition=full","pubTime":"2026-08-25 22:11","pubTimestamp":1787667118,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘，益方生物报收于19.16元，较前一交易日上涨0.52%，最新总市值为111.05亿元。该股当日开盘19.08元，最高19.45元，最低18.23元，成交额达2.93亿元，换手率为2.67%。公告显示，公司将于2026年9月2日10:00-11:00通过上证路演中心网络互动方式召开2026年半年度业绩说明会，介绍公司经营成果及财务状况。投资者可于2026年8月26日至9月1日16:00前通过上证路演中心网站或公司邮箱ir@inventisbio.com提问，公司将在说明会上对普遍关注的问题进行回应。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500050340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661669210","title":"益方生物：重新递交H股发行上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2661669210","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661669210?lang=zh_cn&edition=full","pubTime":"2026-08-23 15:40","pubTimestamp":1787470810,"startTime":"0","endTime":"0","summary":"益方生物(688382.SH)公告称，公司于8月21日重新向香港联交所递交H股发行上市申请，并于同日在香港联交所网站刊登申请资料。该申请材料为草拟版本，投资者不应据此作出投资决定。本次发行上市尚需取得证监会、香港证监会及香港联交所等批准，存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300004171.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661214835","title":"每周股票复盘：益方生物（688382）股东户数减少16.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661214835","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661214835?lang=zh_cn&edition=full","pubTime":"2026-08-23 03:03","pubTimestamp":1787425389,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，益方生物报收于20.0元，较上周的21.09元下跌5.17%。本周，益方生物8月18日盘中最高价报22.64元。股本股东变化股东户数变动截至2026年6月30日，益方生物股东户数为1.48万户，较3月31日减少2960户，减幅为16.7%。本次符合归属条件的激励对象为2名，归属股票数量为1.6518万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110770273","title":"默沙东研发中国签署合作协议，携手益方生物推进小分子肿瘤药物临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1110770273","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110770273?lang=zh_cn&edition=full","pubTime":"2026-08-11 15:39","pubTimestamp":1786433970,"startTime":"0","endTime":"0","summary":"默沙东研发中国（Msd R&D China）宣布，已与益方生物（Inventisbio）正式签署一项合作协议。此次合作旨在共同推进小分子肿瘤药物的临床开发进程。公司在一份声明中披露了该消息，双方将集中资源，致力于加速相关候选药物的研究、试验与申报工作，以期早日为患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLSP4452.SGD","IE0009355771.USD","IE00B2B36J28.USD","LU1066051498.USD","SG9999015341.SGD","LU0203345920.USD","IE00BN8TJ469.HKD","LU0122379950.USD","SG9999014567.USD","LU1066051225.USD","LU2125909593.SGD","LU0477156953.USD","SG9999013999.USD","LU1066053197.SGD","VHT","IYH","LU2360032135.SGD","BK4585","LU0006306889.USD","SG9999001440.SGD","LU1917777945.USD","LU1934455863.HKD","IE00BJT1NW94.SGD","LU2023250843.SGD","IE00B4R5TH58.HKD","LU1201861249.SGD","SG9999014559.SGD","SG9999015358.SGD","LU1116320737.USD","FHLC","LU2433249047.HKD","SG9999001176.USD","LU1037948541.HKD","LU2125154935.USD","LU1066051811.HKD","LU1974910355.USD","LU1291159041.SGD","LU2023250504.SGD","LU0266013472.USD","LU0823416689.USD","IXJ","LU1162221912.USD","PPH","LU0648001328.SGD","LU0689626769.HKD","LU0130517989.USD","LU2491050154.USD","LU1983299246.USD","LU1093756325.SGD","BK4533","LU1941712348.USD","LU0265550946.USD","LU0289739699.SGD","LU1069347547.HKD","RXL","LU0211331839.USD","SG9999014542.SGD","LU0106261372.USD","BMED","LU1571399168.USD","HRTS","LU0130102774.USD","BK0239","LU1430594728.SGD","MRK","LU1116320901.HKD","SG9999001176.SGD","LU1061106388.HKD","LU2357627491.SGD","IE00BFTCPJ56.SGD","LU1929549753.HKD","LU2361044865.SGD","LU0965509283.SGD","BK4550","LU2361045086.USD","LU1934455277.USD","LU2361044949.HKD","LU1989772840.SGD","LU1934455194.USD","JDOC","LU0265550359.USD","BK4534","LU2324357040.USD","LU2112291526.USD","LU2461242641.AUD","BK4588","BK4007","LU0980610538.SGD","PAWZ","LU2106854487.HKD","LU0965508806.USD","LU0124676726.USD","LU0238689110.USD","LU0320765489.SGD","LU2468319806.SGD","LU0861579265.USD","BK4516","LU0098860793.USD","LU0965509101.SGD","TRUH","LU0868494708.USD","IE00B1BXHZ80.USD","LU2089984988.USD","BK4559","LU1093756168.USD","LU1037948897.HKD","LU0058720904.USD","SG9999002232.USD","LU0320765646.SGD","LU2491049909.HKD","LU0942090050.USD","IE00BLSP4239.USD","688382","LU0234572021.USD","LU0868494617.USD","LU1699723380.USD","LU1035773651.USD","SG9999002224.SGD","LU0965509010.AUD","LU0203347892.USD","LU1057294990.SGD","LU1989771016.USD","SG9999014575.USD","LU1989772923.USD","IE00BSNM7G36.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU2125154778.USD","LU0208291251.USD","LU2491050071.SGD","LU1923622614.USD","GDOC","SGXZ57979304.SGD","XLV","LU2125909247.SGD","LU0859254822.USD","LU1585245621.USD","LU0985320562.USD","LU1941712264.USD","IE000M9KFDE8.USD","LU0070302665.USD","LU0432979614.USD","IE00BBT3K403.USD","IHE","LU1023059063.AUD","FTXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658734960","title":"默沙东与益方生物签署合作协议 推进肿瘤领域小分子药物临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2658734960","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658734960?lang=zh_cn&edition=full","pubTime":"2026-08-11 15:35","pubTimestamp":1786433748,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["688382","LU2433249047.HKD","SG9999001176.USD","LU0130517989.USD","LU1989772840.SGD","LU2106854487.HKD","LU2361045086.USD","LU2461242641.AUD","IE0002141913.USD","LU0098860793.USD","PAWZ","RXL","LU0477156953.USD","LU0648001328.SGD","LU2324357040.USD","LU0289739699.SGD","SG9999015341.SGD","GDOC","LU0868494708.USD","LU1974910355.USD","LU0006306889.USD","LU0203345920.USD","MRK","IE00BN8TJ469.HKD","LU1699723380.USD","SG9999015358.SGD","LU0211331839.USD","LU1037948541.HKD","LU0868494617.USD","IE00BJJMRZ35.SGD","BK4534","LU0238689110.USD","IE00BBT3K403.USD","LU1585245621.USD","LU1291159041.SGD","IE00BLSP4452.SGD","BMED","IE00BFTCPJ56.SGD","IXJ","LU1066051811.HKD","LU1989771016.USD","LU2360032135.SGD","IE00B1BXHZ80.USD","LU1983299246.USD","BK0239","LU0965509283.SGD","SG9999013999.USD","LU0124676726.USD","LU0234572021.USD","LU2125154778.USD","IE00BJT1NW94.SGD","LU2491049909.HKD","SG9999001176.SGD","BK4533","LU0265550359.USD","LU1941712348.USD","LU0985320562.USD","LU2468319806.SGD","LU0265550946.USD","LU0203347892.USD","IE00BSNM7G36.USD","XLV","LU0965509010.AUD","LU1037948897.HKD","LU1093756168.USD","BK4007","LU0070302665.USD","LU1116320901.HKD","LU1066051225.USD","LU1934455277.USD","LU1917777945.USD","LU0861579265.USD","IE00B4R5TH58.HKD","LU1066053197.SGD","LU1057294990.SGD","IE000M9KFDE8.USD","LU1923622614.USD","SG9999014542.SGD","LU2357627491.SGD","LU0859254822.USD","FTXH","LU0823416689.USD","LU1066051498.USD","LU1093756325.SGD","LU0965509101.SGD","IE00BLSP4239.USD","IYH","LU0689626769.HKD","LU2491050154.USD","FHLC","PPH","BK4585","LU1941712264.USD","LU2112291526.USD","IE00B2B36J28.USD","LU0106261372.USD","LU0965508806.USD","BK4550","LU2125154935.USD","LU1116320737.USD","LU1430594728.SGD","SG9999014575.USD","LU0266013472.USD","LU1069347547.HKD","LU2491050071.SGD","VHT","SG9999001440.SGD","SG9999002224.SGD","SG9999014559.SGD","LU2125909247.SGD","LU2361044949.HKD","LU0942090050.USD","BK4516","SG9999014567.USD","LU2125909593.SGD","JDOC","BK4559","TRUH","LU0058720904.USD","LU1934455194.USD","IHE","LU1989772923.USD","LU1162221912.USD","SG9999002232.USD","BK4588","LU0320765646.SGD","LU2023250843.SGD","IE0009355771.USD","SGXZ57979304.SGD","LU1023059063.AUD","LU2089984988.USD","LU1201861249.SGD","LU1035773651.USD","LU0432979614.USD","LU1571399168.USD","LU0122379950.USD","LU0980610538.SGD","LU0320765489.SGD","LU2361044865.SGD","LU1929549753.HKD","LU1934455863.HKD","LU2023250504.SGD","LU0208291251.USD","HRTS","LU0130102774.USD","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657563853","title":"股市必读：益方生物（688382）8月4日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2657563853","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657563853?lang=zh_cn&edition=full","pubTime":"2026-08-05 01:30","pubTimestamp":1785864632,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘，益方生物报收于18.69元，下跌0.53%，换手率4.93%，成交量28.6万手，成交额5.38亿元。希望2026年年报细化人力资本投入、员工发展通道及核心人才留存的披露，并说明公司计划通过哪些机制提升人均产出、增强骨干员工稳定性。感谢您对公司人才建设及长期可持续发展的关注。当日关注点交易信息汇总：8月4日主力资金净流出790.89万元，游资资金净流出2499.24万元，散户资金净流入3290.13万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500001662.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654052237","title":"每周股票复盘：益方生物（688382）因股价涨幅达15%登龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2654052237","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654052237?lang=zh_cn&edition=full","pubTime":"2026-07-26 01:44","pubTimestamp":1785001455,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，益方生物报收于23.81元，较上周的22.55元上涨5.59%。本周，益方生物7月22日盘中最高价报28.1元。益方生物当前最新总市值138.0亿元，在化学制药板块市值排名32/149，在两市A股市值排名1272/5200。本周关注点来自交易信息汇总：益方生物因日收盘价格涨幅达到15%登上龙虎榜。此次是近5个交易日内第1次上榜。该专户账号为110971504010002，仅用于新药研发项目募集资金的存放和使用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000349.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653652917","title":"益方生物（688382）披露签订募集资金专户存储四方监管协议公告，7月22日股价下跌1.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653652917","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653652917?lang=zh_cn&edition=full","pubTime":"2026-07-22 22:12","pubTimestamp":1784729539,"startTime":"0","endTime":"0","summary":"截至2026年7月22日收盘，益方生物报收于25.56元，较前一交易日下跌1.65%，最新总市值为148.14亿元。该股当日开盘25.6元，最高28.1元，最低25.2元，成交额达8.52亿元，换手率为5.53%。近日，益方生物发布关于签订募集资金专户存储四方监管协议的公告。公告显示，公司全资子公司益祺生物科技（北京）有限公司开立募集资金专项账户，用于募投项目“新药研发项目”。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200047277.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649615001","title":"股市必读：益方生物（688382）登7月3日交易所龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2649615001","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649615001?lang=zh_cn&edition=full","pubTime":"2026-07-06 01:17","pubTimestamp":1783271828,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，益方生物报收于22.76元，上涨6.21%，换手率5.12%，成交量29.69万手，成交额6.61亿元。龙虎榜上榜益方生物因有价格涨跌幅限制的连续3个交易日内收盘价格涨幅偏离值累计达到30%，于2026年7月3日登上沪深交易所龙虎榜；此次为近5个交易日内第1次上榜。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600000440.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648650998","title":"7月3日益方生物（688382）龙虎榜数据：机构净买入1.22亿元，北向资金净卖出7665.08万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2648650998","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648650998?lang=zh_cn&edition=full","pubTime":"2026-07-03 17:44","pubTimestamp":1783071878,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年7月3日公布的交易公开信息显示，益方生物因有价格涨跌幅限制的连续3个交易日内收盘价格涨幅偏离值累计达到30%的证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年7月3日收盘，益方生物报收于22.76元，上涨6.21%，换手率5.12%，成交量29.69万手，成交额6.61亿元。从龙虎榜公布的当日买卖数据来看，机构合计净买入1.22亿元，北向资金合计净卖出7665.08万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300032993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648685030","title":"益方生物（688382）披露关于变更公司注册资本并修订《公司章程》的公告，7月2日股价上涨4.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648685030","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648685030?lang=zh_cn&edition=full","pubTime":"2026-07-02 22:24","pubTimestamp":1783002259,"startTime":"0","endTime":"0","summary":"近日，益方生物科技（上海）股份有限公司发布《关于变更公司注册资本并修订〈公司章程〉的公告》。公告显示，公司于2026年6月30日召开第二届董事会2026年第八次会议，审议通过变更注册资本并修订《公司章程》的议案。因2022年限制性股票激励计划部分股份完成归属，公司股本总数由578,348,491股增至579,592,004股，注册资本由578,348,491元增至579,592,004元。《公司章程》第六条和第二十二条相应修订，其他条款不变。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200042090.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648799524","title":"新股消息 | 益方生物(688382.SH)港股IPO招股书失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2648799524","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648799524?lang=zh_cn&edition=full","pubTime":"2026-07-02 06:41","pubTimestamp":1782945678,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，益方生物科技(上海)股份有限公司于2026年1月1日所递交的港股招股书满6个月，于2026年7月1日失效，中信证券为其独家保荐人。据此前招股书，益方生物是一家立足中国、布局全球的研发驱动型生物制药公司，专注于肿瘤、自身免疫性疾病及代谢性疾病等存在大量未被满足需求的重大疾病领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462044.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK0239","688382","BK4588","BK4585","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646916313","title":"每周股票复盘：益方生物（688382）授出657.0981万股限售股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646916313","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646916313?lang=zh_cn&edition=full","pubTime":"2026-06-28 02:14","pubTimestamp":1782584053,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，益方生物报收于15.96元，较上周的17.19元下跌7.16%。本周关注点公司公告汇总：益方生物向183名激励对象授出657.0981万股限制性股票，授予价格为10.55元/股。因1名激励对象离职，激励对象人数由184人调整为183人，限制性股票总量657.0981万股保持不变。其中，董事、财务总监史陆伟获授50.1952万股，占授予总数的7.64%；182名骨干人员合计获授606.9029万股，占授予总数的92.36%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800000512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645081954","title":"益方生物（688382）发布向2026年限制性股票激励计划激励对象授予限制性股票的公告，6月24日股价上涨3.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645081954","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645081954?lang=zh_cn&edition=full","pubTime":"2026-06-24 22:15","pubTimestamp":1782310517,"startTime":"0","endTime":"0","summary":"截至2026年6月24日收盘，益方生物报收于17.4元，较前一交易日上涨3.02%，最新总市值为100.85亿元。近日，益方生物科技（上海）股份有限公司发布《关于向2026年限制性股票激励计划激励对象授予限制性股票的公告》。本次授予的限制性股票将在授予日起12个月后分三期归属，归属比例分别为40%、40%、20%。该激励计划有效期最长不超过60个月。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400043838.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644063712","title":"每周股票复盘：益方生物（688382）2026年限制性股票激励计划获通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2644063712","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644063712?lang=zh_cn&edition=full","pubTime":"2026-06-20 02:33","pubTimestamp":1781893989,"startTime":"0","endTime":"0","summary":"本次股东会于2026年6月18日以现场与网络投票相结合的方式召开，审议通过了董事会工作报告、年度报告、利润分配方案、董事及高管薪酬、限制性股票激励计划等议案。关于公司2026年限制性股票激励计划内幕信息知情人买卖公司股票情况的自查报告指出，在自查期间，共有2名内幕信息知情人存在买卖公司股票的行为，其交易系基于公开信息和个人判断作出，不存在利用内幕信息进行交易的情形。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000000757.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644846670","title":"益方生物（688382）披露2025年年度股东会决议公告，6月18日股价上涨2.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644846670","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644846670?lang=zh_cn&edition=full","pubTime":"2026-06-18 22:34","pubTimestamp":1781793259,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，益方生物报收于17.19元，较前一交易日上涨2.81%，最新总市值为99.63亿元。该股当日开盘16.6元，最高17.62元，最低16.4元，成交额达2.24亿元，换手率为2.26%。近日，益方生物科技（上海）股份有限公司发布《2025年年度股东会决议公告》。会议表决程序合法有效，无被否决议案。关联股东对相关议案回避表决，中小投资者对多项议案单独计票。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800042676.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641127878","title":"每周股票复盘：益方生物（688382）新增1,243,513股上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2641127878","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2641127878?lang=zh_cn&edition=full","pubTime":"2026-06-07 02:04","pubTimestamp":1780769053,"startTime":"0","endTime":"0","summary":"截至2026年6月5日收盘，益方生物报收于17.59元，较上周的19.5元下跌9.79%。益方生物当前最新总市值101.95亿元，在化学制药板块市值排名47/150，在两市A股市值排名1919/5206。本次归属新增股份1,243,513股，上市流通日为2026年6月5日，股票来源为公司向激励对象定向发行A股普通股。归属完成后公司总股本增至579,592,004股，控股股东持股比例未发生变动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060700000542.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791421326453,"stockEarnings":[{"period":"1week","weight":-0.0422},{"period":"1month","weight":-0.0403},{"period":"3month","weight":-0.1101},{"period":"6month","weight":-0.1636},{"period":"1year","weight":-0.387},{"period":"ytd","weight":-0.2999}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0362},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.0098},{"period":"1year","weight":-0.0105},{"period":"ytd","weight":-0.0319}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"益方生物科技(上海)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"14766人(较上一季度减少16.70%)","perCapita":"39251股","listingDate":"2022-07-25","address":"上海市浦东新区中国(上海)自由贸易试验区李冰路67弄4号210室","registeredCapital":"57959万元","survey":" 益方生物科技(上海)股份有限公司的主营业务是创新药物的研发、生产和销售。公司的主要产品是贝福替尼、格索雷塞。","listedPrice":18.12},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"益方生物-U(688382)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供益方生物-U(688382)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"益方生物-U,688382,益方生物-U股票,益方生物-U股票老虎,益方生物-U股票老虎国际,益方生物-U行情,益方生物-U股票行情,益方生物-U股价,益方生物-U股市,益方生物-U股票价格,益方生物-U股票交易,益方生物-U股票购买,益方生物-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"益方生物-U(688382)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供益方生物-U(688382)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}